A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more personalized treatment.

Dr. Bodei notes that there are differences between PET versus SPECT. PET has high sensitivity and is a biological signal, whereas SPECT is therapy linked and used in dosimetry. SPECT also informs ...

The transition to a new PSMA PET formulation is scheduled for Q4 2026 on a rolling regional basis to ensure seamless supply and reimbursement coverage. Guidance for PYLARIFY assumes an 8%-10% revenue ...

China approved on Thursday an innovative nuclear medicine imaging agent developed by a research team led by Professor Wang Fan at Peking University. The agent is the world's first radioactive drug ...

Evaluation of de novo oligometastatic prostate cancer patients managed with radiation therapy: A multi-institution, real-world dataset. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Bone SPECT/CT imaging – the integration of functional single photon emission computed tomography with anatomical computed tomography – represents a significant advancement in the evaluation of foot ...

BEDFORD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc., the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver ...

Chengdu Brilliant Pharmaceutical Co. Ltd. and Chengdu Xinke Pharmaceutical Co. Ltd. have disclosed drug conjugates comprising a bone-targeting moiety covalently bound to a radiolabeled-chelating agent ...

Prognostic value of quantitative PSMA-PET parameters during chemotherapy in prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not ...